Loading...

Nanollose Limited

NC6.AXASX
Healthcare
Biotechnology
A$0.07
A$-0.01(-10.26%)

Nanollose Limited (NC6.AX) Financial Performance & Income Statement Overview

Analyze Nanollose Limited (NC6.AX) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
-96.97%
96.97%
Operating Income Growth
1.78%
1.78%
Net Income Growth
14.05%
14.05%
Operating Cash Flow Growth
10.92%
10.92%
Operating Margin
-7974.08%
7974.08%
Gross Margin
-1477.91%
1477.91%
Net Profit Margin
-8208.56%
8208.56%
ROE
342.35%
342.35%
ROIC
231.10%
231.10%

Nanollose Limited (NC6.AX) Income Statement & Financial Overview

Analyze Nanollose Limited’s NC6.AX earnings with segmented quarterly and yearly financial statement figures.

MetricQ2 2025Q4 2024Q2 2024Q4 2023
Revenue$5007.00$11626.00$292413.00$412164.00
Cost of Revenue$129552.00$132902.00$228551.00$163362.00
Gross Profit-$124545.00-$121276.00$63862.00$248802.00
Gross Profit Ratio-$24.87-$10.43$0.22$0.60
R&D Expenses$129552.00$132902.00$228551.00$163362.00
SG&A Expenses$440321.00$377733.00$453225.00$474615.00
Operating Expenses$569873.00$510635.00$681776.00$637977.00
Total Costs & Expenses$699425.00$643537.00$910327.00$801339.00
Interest Income$0.00$1864.00$2580.00$5665.00
Interest Expense$0.00$9803.00$12076.00$432.00
Depreciation & Amortization$17283.00-$9192.00$17027.00-$15870.00
EBITDA-$691560.00-$641510.00-$506391.00-$356185.00
EBITDA Ratio-$138.12-$55.18-$1.73-$0.86
Operating Income-$694418.00-$631911.00-$617914.00-$389175.00
Operating Income Ratio-$138.69-$54.35-$2.11-$0.94
Other Income/Expenses (Net)-$31263.00-$7738.00$101010.00$23394.00
Income Before Tax-$725681.00-$639649.00-$516904.00-$365781.00
Income Before Tax Ratio-$144.93-$55.02-$1.77-$0.89
Income Tax Expense$0.00$0.00$0.00$0.00
Net Income-$725681.00-$639649.00-$516904.00-$365781.00
Net Income Ratio-$144.93-$55.02-$1.77-$0.89
EPS-$0.004-$0.004-$0.003-$0.002
Diluted EPS-$0.004-$0.004-$0.003-$0.002
Weighted Avg Shares Outstanding$172.78M$158.84M$161.53M$149.36M
Weighted Avg Shares Outstanding (Diluted)$172.78M$158.83M$161.53M$149.31M

The company's financials show resilient growth, with revenue advancing from $412164.00 in Q4 2023 to $5007.00 in Q2 2025. Gross profit remained healthy with margins at -2487% in Q2 2025 compared to 60% in Q4 2023. Operating income hit -$694418.00 last quarter, sustaining a consistent -13869% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$691560.00. Net income dropped to -$725681.00, while earnings per share reached -$0.004. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;